• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Forbion European Acquisition Corp.

    10/24/23 5:10:02 PM ET
    $FRBN
    Blank Checks
    Finance
    Get the next $FRBN alert in real time by email
    8-K
    00-0000000 GRAND CAYMAN false 0001874495 0001874495 2023-10-24 2023-10-24 0001874495 frbn:Class160AOrdinarySharesParValue0.0001PerShareMember 2023-10-24 2023-10-24 0001874495 frbn:RedeemableWarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf11.50Member 2023-10-24 2023-10-24 0001874495 frbn:UnitsEachConsistingOfOneClassAOrdinaryShareAndOneThirdOfOneRedeemableWarrantMember 2023-10-24 2023-10-24

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):

    October 24, 2023

     

     

    FORBION EUROPEAN ACQUISITION CORP.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Cayman Islands   001-41148   N/A

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    4001 Kennett Pike, Suite 302

    Wilmington, Delaware

      19807
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s telephone number, including area code: +1 732 838-4533

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☒

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Class A ordinary shares, par value $0.0001 per share   FRBN   The Nasdaq Stock Market LLC
    Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50   FRBNW   The Nasdaq Stock Market LLC
    Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant   FRBNU   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.07. Submission of Matters to a Vote of Security Holders.

    On October 24, 2023, Forbion European Acquisition Corp. (the “Company” or “FEAC”) held an extraordinary general meeting (the “Special Meeting”) of the shareholders of the Company. Set forth below are the final voting results for each of the five proposals submitted to a vote of the shareholders of the Company at the Special Meeting:

     

              Votes For      Votes
    Against
         Abstentions
    1.    Proposal No. 1 – The Business Combination Proposal - A proposal to, as a special resolution, approve and adopt the Business Combination Agreement (the “Business Combination Agreement”), dated as of May 16, 2023 by and among FEAC, enGene Inc. a corporation incorporated under the laws of Canada (“enGene”), and enGene Holdings Inc., a corporation incorporated under the laws of Canada (“New enGene”), and the transactions contemplated therein, whereby, among other things, FEAC, enGene and New enGene will complete a business combination (the “Business Combination”).      12,859,867        589,064      0
              Votes For      Votes
    Against
         Abstentions
    2.    Proposal No. 2 – The Governing Documents Proposal - A proposal to, as an ordinary resolution, approve the following material differences between the articles of New enGene to be in effect following the Business Combination (the “Proposed Articles”) and FEAC’s current Amended and Restated Memorandum and Articles of Association (the “Current Articles”): (i) the name of the new public entity will be “enGene Holdings Inc.” as opposed to “Forbion European Acquisition Corp.”; (ii) New enGene will have an unlimited number of authorized common shares and an unlimited number of authorized blank cheque preferred shares, as opposed to FEAC having 500,000,000 Class A ordinary shares authorized, 50,000,000 Class B ordinary shares authorized and 5,000,000 preference shares authorized; (iii) New enGene’s Proposed Articles would reduce the requisite quorum for a meeting of shareholders from a majority of votes as required under the Current Articles to 33 1/3% of the shares entitled to vote at such meeting; (iv) New enGene’s Proposed Articles would include an advance notice provision that requires a nominating shareholder to provide notice to New enGene in advance of a meeting of shareholders should such nominating shareholder wish to nominate a person for election to the board of directors; (v) New enGene’s corporate existence will be perpetual as opposed to FEAC’s corporate existence terminating if the initial business combination is not consummated by FEAC within a specified period of time; and (vi) New enGene’s constitutional documents will not include the various provisions applicable only to special purpose acquisition corporations that FEAC’s Current Articles contain.      12,299,527        1,149,404      0
              Votes For      Votes
    Against
         Abstentions
    3.    Proposal No. 3 – The Nasdaq Proposal - A proposal to, as an ordinary resolution, for purposes of complying with Nasdaq Listing Rule 5635(a), (b) and (d), approve the issuance of more than 20% of the issued and outstanding FEAC Class A ordinary shares and the resulting change in control in connection with the Business Combination.      12,859,867        589,064      0
              Votes For      Votes
    Against
         Abstentions
    4.    Proposal No. 4 – The Incentive Equity Plan Proposal - A proposal to, as an ordinary resolution, approve the enGene Holdings Inc. 2023 Incentive Equity Plan.      11,602,725        1,846,206      0


              Votes For      Votes
    Against
         Abstentions
    5.    Proposal No. 5 – The Adjournment Proposal - A proposal to, as an ordinary resolution, approve the adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Special Meeting, any of the condition precedent proposals would not be duly approved and adopted by FEAC shareholders or FEAC determines that one or more of the closing conditions under the Business Combination Agreement is not satisfied or waived.      12,859,766        589,063      102

    Based upon the submission of proxies and ballots, a majority of the shares of FEAC ordinary shares issued and outstanding and entitled to vote at the close of business on the record date were present at the Special Meeting by proxy or by attendance via the virtual meeting website, which constituted a quorum. Proposal No. 1 was approved by the required vote. Proposal No. 2 was approved by the required vote. Proposal No. 3 was approved by the required vote. Proposal No. 4 was approved by the required vote. Proposal No. 5 was approved by the required vote.


    Item 8.01. Other Events.

    In connection with the shareholder vote at the Special Meeting, FEAC’s public shareholders had the right to elect to redeem all or a portion of their Class A ordinary shares for a per share price calculated in accordance with FEAC’s organizational documents. FEAC’s public shareholders holding 10,379,144 Class A ordinary shares validly elected to redeem their public shares.

    The closing of the Company’s Business Combination is expected to occur on or about October 31, 2023, subject to the satisfaction or waiver of the conditions with respect to the Business Combination.


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Dated: October 24, 2023

     

    FORBION EUROPEAN ACQUISITION CORP.
    By:  

    /s/ Jasper Bos

      Jasper Bos
      Chief Executive Officer
    Get the next $FRBN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FRBN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FRBN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Forbion Growth Sponsor Feac I B.V. returned 3,373,496 units of Class A Ordinary Shares to the company (SEC Form 4)

    4 - Forbion European Acquisition Corp. (0001874495) (Issuer)

    10/31/23 7:05:31 PM ET
    $FRBN
    Blank Checks
    Finance

    Forbion Growth Sponsor Feac I B.V. converted options into 1,373,496 units of Class A Ordinary Shares (SEC Form 4)

    4 - Forbion European Acquisition Corp. (0001874495) (Issuer)

    10/31/23 6:59:26 PM ET
    $FRBN
    Blank Checks
    Finance

    New insider Forbion Growth Sponsor Feac I B.V. claimed ownership of 2,000,000 units of Class A Ordinary Shares (SEC Form 3) (Amendment)

    3/A - Forbion European Acquisition Corp. (0001874495) (Issuer)

    10/31/23 6:12:51 PM ET
    $FRBN
    Blank Checks
    Finance

    $FRBN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer

    BOSTON and MONTREAL, Sept. 7, 2023 /PRNewswire/ - enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs, today announced the appointment of Richard Bryce, MBChB, MRCGP, MFPM as its Chief Medical Officer, effective September 19, 2023. Dr. Bryce will oversee the clin­i­cal develop­ment of EG-70, enGene's lead product candidate for non-muscle invasive bladder cancer (NMIBC), as well as the devel­op­ment strat­e­gy for enGene's ther­a­peu­tic pipeline of tissue-targeted non-viral gene therapies.

    9/7/23 7:00:00 AM ET
    $FRBN
    Blank Checks
    Finance

    enGene, Inc. and Forbion European Acquisition Corp. ("FEAC", Nasdaq: FRBN) Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company Developing Next-Generation Non-Viral, Locally Administered Gene Therapies

    Leading institutional investors commit $135 million USD in transaction financing, anchored by FEAC's sponsor, Forbion Growth Sponsor FEAC I B.V. (together with its parent entity Forbion Growth Opportunities Fund I Cooperatief U.A., "Forbion Growth").enGene is a clinical-stage biotechnology company developing non-viral gene therapies based on its proprietary dually derivatized chitosan ("DDX") platform that are re-dosable, manufacturable at scale and designed to be seamlessly integrated into community clinical practices across the globe.Net proceeds are expected to be used to finance enGene's operations through multiple potential value inflection milestones towards a potential Biologics Licen

    5/17/23 7:00:28 AM ET
    $FRBN
    Blank Checks
    Finance

    VectivBio Announces Results of Extraordinary General Meeting

    BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022. Mr. Wouter Joustra brings a breadth of capital markets and investment experience in the life sciences investment industry to VectivBio. He joined Forbion, a leading European life sciences venture capital firm, in October 2019, where he is currently General Partner. At Forbion, Mr. Joustra is responsible for deal originatio

    12/9/22 4:01:00 PM ET
    $FRBN
    $VECT
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FRBN
    SEC Filings

    View All

    SEC Form 15-12G filed by Forbion European Acquisition Corp.

    15-12G - Forbion European Acquisition Corp. (0001874495) (Filer)

    11/13/23 6:45:16 AM ET
    $FRBN
    Blank Checks
    Finance

    Forbion European Acquisition Corp. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Regulation FD Disclosure

    8-K - Forbion European Acquisition Corp. (0001874495) (Filer)

    11/1/23 5:53:05 PM ET
    $FRBN
    Blank Checks
    Finance

    SEC Form 25-NSE filed by Forbion European Acquisition Corp.

    25-NSE - Forbion European Acquisition Corp. (0001874495) (Subject)

    10/31/23 5:07:48 PM ET
    $FRBN
    Blank Checks
    Finance

    $FRBN
    Leadership Updates

    Live Leadership Updates

    View All

    enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer

    BOSTON and MONTREAL, Sept. 7, 2023 /PRNewswire/ - enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs, today announced the appointment of Richard Bryce, MBChB, MRCGP, MFPM as its Chief Medical Officer, effective September 19, 2023. Dr. Bryce will oversee the clin­i­cal develop­ment of EG-70, enGene's lead product candidate for non-muscle invasive bladder cancer (NMIBC), as well as the devel­op­ment strat­e­gy for enGene's ther­a­peu­tic pipeline of tissue-targeted non-viral gene therapies.

    9/7/23 7:00:00 AM ET
    $FRBN
    Blank Checks
    Finance

    $FRBN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Forbion European Acquisition Corp. (Amendment)

    SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)

    2/14/24 4:55:28 PM ET
    $FRBN
    Blank Checks
    Finance

    SEC Form SC 13G filed by Forbion European Acquisition Corp.

    SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)

    2/14/24 6:00:38 AM ET
    $FRBN
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Forbion European Acquisition Corp. (Amendment)

    SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)

    2/8/24 12:51:47 PM ET
    $FRBN
    Blank Checks
    Finance